Navigation Links
Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software
Date:8/7/2008

NEW YORK, Aug. 7 /PRNewswire-FirstCall/ -- Medicsight PLC, a subsidiary of MGT Capital Investments, Inc. (Amex: MGT), and an industry leader in the development of Computer-Aided Detection (CAD) and image analysis software, today announced that it has received approval from the Brazilian regulatory agency, Agencia Nacional de Vigilancia Sanitaria ("ANVISA"), for its ColonCAD(TM) software.

David Sumner, Chief Executive of Medicsight, commented: "This is another important milestone for Medicsight and our partners as we commercialize our technology globally. This regulatory approval in the dynamic Latin American market is another approval in a high growth BRIC market, following on from the Chinese State Food and Drug Administration approval announced in April."

Dr. Stuart Taylor of University College Hospital, London, a principal investigator for Medicsight, commented: "The approval of Medicsight's ColonCAD(TM) software is great news for patients. It will also be a bonus for radiologists, whose workload is growing rapidly, both due to the rising prevalence of colorectal cancer and the advances in imaging technology which have led to a substantial increase in the amount of image data that must be reviewed for each patient scan. Medicsight's technology can help to ease this burden, potentially reducing human error and also providing a valuable tool, especially for less experienced readers, to interpret these complex scans.

"Medicsight's CAD software has been validated against one of the world's largest and most population diverse proprietary databases of verified CT scan data, making the software applicable to patients of many different nationalities," concluded Dr. Taylor.

Medicsight's ColonCAD(TM) computer-aided detection technology aims to assist radiologists in the detection of colorectal neoplasia (polyps) by automatically highlighting suspicious areas on CT colonography scan images. The software may also help radiologists detect potentially malignant tumours at an early stage when treatment is most likely to be successful.

About MGT Capital Investments, Inc.

MGT Capital Investments, Inc. is a technology holding company that focuses on investments in the global healthcare information technology market. The Company has two subsidiaries, Medicsight PLC and Medicexchange PLC.

Medicsight PLC (AIM: MDST) is a UK-headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software automatically highlights suspicious areas on computerised tomography (CT) scans of the colon and lung, helping radiologists to identify, measure and analyse potential disease and early indicators of disease. Medicsight's CAD software has been validated using one of the world's largest and most population diverse databases of verified patient CT scan data. Medicsight's ColonCAD(TM) and LungCAD(TM) software products are seamlessly integrated with the advanced 3D visualisation workstations of several industry-leading imaging equipment partners.

Medicexchange PLC provides medical imaging professionals with a global web portal containing an online sales, jobs and information channel for diagnostic, treatment and surgery planning solutions. This combined with a variety of relevant clinical papers, training materials and content gives these professionals access to information and products that they otherwise would have difficulty accessing.

Additional information can be found at http://www.mgtci.com.

All forward-looking statements are made pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current management expectations that involve risks and uncertainties that may result in such expectations not being realized. Potential risks and uncertainties include, but are not limited to, the risks described in company filings with the Securities and Exchange Commission.

Investor & Media enquiries:

KCSA Strategic Communications

Todd Fromer / Garth Russell

Tel: +1 212-896-1215 / 212-896-1250

tfromer@kcsa.com / grussell@kcsa.com


'/>"/>
SOURCE MGT Capital Investments, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medicsight to Present at Piper Jaffray Annual Europe Conference
2. Medicsight Announces Chinese State Food and Drug Administration Approval for MedicRead Colon Workstation
3. Medicsight Announces New Marketing Partnership with INFINITT
4. Medicsight Welcomes U.S. Initiative to Reimburse CT Colonography for Early Detection of Colorectal Cancer
5. ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission
6. Kiwa Bio-Tech Receives Nationally Recognized Organic Products Certification
7. Alfacell Receives NASDAQ Delisting Letter
8. Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent
9. Workforce Alliance Receives U.S. Labor Departments Excellence Award
10. Osteotechs Plexur M(TM) Biocomposite Receives FDA Clearance in Spine
11. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Research and Markets has announced the addition of ... offering. ... The Global Market for Bioproducts Should Reach $714.6 Billion ... of 8.9%, This research report quantifies the ... product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), biocomposite ...
(Date:3/23/2017)... 23, 2017  SeraCare Life Sciences, Inc., a ... vitro diagnostics manufacturers and clinical laboratories, is ... multiplexed Inherited Cancer reference material ... next-generation sequencing (NGS). The Seraseq™ Inherited Cancer DNA ... from industry experts to validate the ability ...
(Date:3/23/2017)... March 23, 2017  BioPharmX Corporation (NYSE MKT: ... the dermatology market, today reported financial results for ... and will provide an update on the company,s ... "We are pleased to report that ... BioPharmX," said President Anja Krammer. "We achieved key ...
(Date:3/23/2017)... , March 23, 2017 Kineta, Inc., ... of novel therapies in immuno-oncology, today announced the ... small molecule compounds that activate interferon response factor ... and demonstrate immune-mediated tumor regression in a murine ... study who demonstrated complete tumor regression to initial ...
Breaking Biology Technology:
(Date:3/6/2017)... , March 6, 2017 Mintigo ... technology, today announced Predictive Sales Coach TM , ... actionable sales intelligence into Salesforce. This unique AI ... their sales organizations with deep knowledge of their ... for intelligent engagement. Predictive Sales Coach extends Mintigo,s ...
(Date:3/2/2017)... 2017 Australian stem cell and regenerative medicine ... signed an agreement with the Monash Lung Biology Network, ... Institute and Department of Pharmacology at Monash University, ... study to support the use of Cymerus™ mesenchymal stem ... Asthma is a chronic, long term lung condition ...
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ein ... wird seine erstklassige biometrische Lösung zur Iris-Erkennung ... mit X16 LTE auf dem Mobile World ... am Qualcomm-Stand in Halle 3, Stand 3E10, ... die Sicherheitsplattform Qualcomm Haven™ – eine Kombination ...
Breaking Biology News(10 mins):